Endocrine Abstracts

Introduction: LMTK3 is an oncogenic Receptor Tyrosine Kinase (RTK) implicated in resistance to endocrine therapy in breast cancer. Initially, LMTK3 was described as a regulator of Estrogen Receptor alpha (ERα) since it was found able to protect it from ubiquitin-mediated proteasomal degradation. In a cohort of breast cancer (BC) patients (n>600), LMTK3 protein levels and intronic polymorphisms were significantly associated with disease-free and overall surviv...